						U7/4/471EHeet 1 of 1						
FORM PTO-1449 MODIFIED		U.S. I RTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DO TT NO. 175931			SERIAL NO. Unassigned			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT						Rec'd PCT/PTO 2.3 NOV 1999 APPLICANT Mitchell et al.						
(Use several sheets if necessary)										GROUP Unassigned		
			U.S. PAT	ENT DOCUMEN	VT:	S						
Examiner's Initials		PATENT Number				CLASS SUE			]		G DATE IF PRIATE	
	<u> </u>											
	1								+			
	<del> </del>											
			-									
											_	
										•		
	<u> </u>											
	ļ			<del>                                     </del>		_			<u> </u>			
	-			-								
	<del>                                      </del>											
	<del> </del>							:				
	1											
FOREIGN PATENT DOCUMENTS  DOCUMENT PUBLICATION TRANSLATIO												
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	Y		CLASS	SUBCLA	SUBCLASS YES		No*	
	AA	WO 96/40127	Dec. 19, 1996	WIPO								
								•				
·	1										-	
		I	L,				_		L			

AB Monti et al., "Cytotoxicity of Tempol, a Piperidine Nitroxyde Spin Label, Against Different Neoplastic and Non-Neoplastic Cell Lines," PAACR Annual Meeting, 36, 387 (1995).

AC Monti et al., "DNA Damage and Apoptosis in Human Leukemic Cells Treated with the Piperidine Nitroxyde Tempol," PAACR Annual Meeting, 38, 193 (1997).

AD Monti et al., "The Piperidine Nitroxyde Tempol Induced Apoptosis and P21-WAF1-CIP1 Expression in P53-Deficient Cells," PAACR Annual Meeting, 39, 90 (1998).

EXAMINER DATE CONSIDERED /- 2} -0/

<sup>\*</sup>A concise statement of relevance is being submitted in lieu of a translation. 37 CFR § 1.98(b). 1449FORM (Rev. 7/15/1999)